Teva’s Baeder: We Need To ‘Crack The Nut’ Of Complex Generics

US Generics Division COO Says Optimum Environment Needs To Be Created

Industry and regulators need to collaborate to provide complex generics with the opportunity to build even further on the significant contributions already made by off-patent medicines to savings and access, Christine Baeder, senior vice president and chief operating officer of Teva’s US generics division, tells Generics Bulletin in the first part of an exclusive interview.

Christine Baeder
Teva’s Christine Baeder sets out her view of complex generics in the US • Source: Teva

When Teva published its economic impact report for 2020 earlier this year, the numbers were a reminder of the significant impact that generic medicines have on healthcare systems worldwide.

Across 14 countries, the company said it had contributed savings to healthcare systems of $43.1bn in 2020. Of this total,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Irish Ruling Gives Go-Ahead For Endo-Mallinckrodt Merger

 
• By 

A ruling from Ireland’s High Court has cleared the way for Endo and Mallinckrodt to consummate their merger in early August.

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

Adalvo Changes Hands As EQT Takes Control

 
• By 

Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.

Amphastar Unveils Plans To Quadruple US Manufacturing

 
• By 

Amphastar has announced plans to quadruple its domestic production capacity over the next three to five years. The move plays into a growing trend towards US manufacturing localization, against the backdrop of potential pharmaceutical tariffs being mooted by the Trump administration.

More from Business

Adalvo Changes Hands As EQT Takes Control

 
• By 

Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.

Amphastar Unveils Plans To Quadruple US Manufacturing

 
• By 

Amphastar has announced plans to quadruple its domestic production capacity over the next three to five years. The move plays into a growing trend towards US manufacturing localization, against the backdrop of potential pharmaceutical tariffs being mooted by the Trump administration.

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By 

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.